TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20701121
Drug: Tpanax Notoginseng
Normalized name: Panax notoginseng root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tpanax Notoginseng pills (4 g, twice daily)
Study: 20701121
Drug: Tpanax Notoginseng
Normalized name: Panax notoginseng root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tpanax Notoginseng pills (4 g, twice daily) and Lornoxicam injection (8 mg, once daily)
Study: 20701121
Drug: Tpanax Notoginseng
Normalized name: Panax notoginseng root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tpanax Notoginseng pills (4 g, twice daily), Lornoxicam injection (8 mg, once daily), and Tongmai decoction (200 ml, twice daily)
Study: 14659344
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with nomegestrol acetate (NOMAC)
Study: 15758600
Drug: Antithrombotic agents
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic agents
Study: 1385826
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test reactions to 11 common organic allergens
Study: 1385826
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test control (0.4% phenol and 50% glycerin in 0.9% saline)
Study: 29121274
Drug: Standard temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard temozolomide with crossover to BEV second-line therapy
Study: 25271049
Drug: β-blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker use in prior MI cohort
Study: 25271049
Drug: β-blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker use in known atherothrombotic disease cohort
Study: 25271049
Drug: β-blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker use in risk factors alone cohort
Study: 17979860
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTX‐A) injections (3 injections at 0, 6, and 18 months; dose 0.5-2.1 units/kg, mean 1.5 [SD 0.18]; dilution 100 units/0.5 ml)
Study: 17979860
Drug: Delayed group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed group (2 injections at 6 and 18 months)
Study: 14717945
Drug: Calcitriol therapy
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol therapy (0.5 microg/48 h) plus oral calcium supplementation (0.5 g/day) for 1 year
Study: 11591835
Drug: Clomethiazole (68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomethiazole (68 mg/kg IV over 24 hours)
Study: 7827649
Drug: 3 different
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 different drug regimes
Study: 2683908
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg administered sublingually)
Study: 18717710
Drug: Classic ketogenic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic ketogenic diet (KD) with glucose (60 g/day)
Study: 14698679
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) 100 microg bolus injection
Study: 14698679
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) 150 microg infusion
Study: 1573045
Drug: Buspirone 5
Normalized name: busPIRone 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 5 mg three times a day for the first week, then 10 mg in the morning, 5 mg in the afternoon, and 5 mg in the evening for the next three weeks.
Study: 1573045
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg three times a day for all 4 weeks.
Study: 1573045
Drug: Driving performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Driving performance test after each treatment week.
Study: 3993625
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (DTIC, DTIC/CCNU/vincristine)
Study: 3993625
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no further treatment after surgery)
Study: 26638185
Drug: Control (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (weekly mailings)
Study: 22693238
Drug: Caffeine (CAFF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAFF) 3 mg/kg body mass
Study: 22693238
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (SB) 0.3 g · kg⁻¹ · BM⁻¹
Study: 18332706
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion at 2.5-3.0 g/kg/day
Study: 18332706
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion at 4.0 g/kg/day
Study: 16260639
Drug: Clopidogrel 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 900 mg
Study: 10381666
Drug: Corticosteroids (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (starting doses of 60-1000 mg per day, reduced to 40-50 mg per day after 4-6 weeks)
Study: 10381666
Drug: Corticosteroids (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (conventional dose 60-80 mg per day vs very high doses 200-1000 mg per day)
Study: 10381666
Drug: Corticosteroids (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (various doses)
Study: 7594326
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg and AMPC 1,500 mg
Study: 7594326
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg alone
Study: 120339
Drug: AMCA (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMCA (160 mg/extraction site)
Study: 31280035
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) combined with medication
Study: 23224592
Drug: Parental trait
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental trait anxiety in treatment responders
Study: 18471454
Drug: Niacin extended
Normalized name: Niacin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin extended release plus simvastatin (NER/S) 1,000/20 mg/day
Study: 18471454
Drug: Niacin extended
Normalized name: Niacin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin extended release plus simvastatin (NER/S) 2,000/20 mg/day
Study: 16936391
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 20 mg/day for 2 weeks followed by 10 mg/day for 2 weeks
Study: 14657842
Drug: Oral antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamines
Study: 10690544
Drug: Treatment-induced minimum
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-induced minimum NSE values
Study: 10690544
Drug: Etoposide and
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide and cisplatin treatment (4 to 6 cycles)
Study: 10431879
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin
Study: 3884406
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg 3 times daily orally)
Study: 27094495
Drug: Neurodynamic mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodynamic mobilization group (manual therapy and neurodynamic techniques)
Study: 27094495
Drug: Electrophysical modalities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysical modalities group (red and infrared laser and ultrasound therapy)
Study: 24428467
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg orally once daily) plus sofosbuvir (400 mg orally once daily) for 12 or 24 weeks, with or without ribavirin
Study: 18408224
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + reduced-dose interferon (IFN) 6 or 3 MIU
Study: 18408224
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + reduced-dose IFN
Study: 6617242
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg indapamide + methyldopa (average 1100 mg daily)
Study: 6617242
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide + methyldopa (average 1575 mg daily)
Study: 6617242
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg indapamide (Step 1 medication only)
Study: 6617242
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg indapamide (Step 1) and 50 mg hydrochlorothiazide (Step 1)
Study: 31806127
Drug: Conventional prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional prophylactic antibiotic treatment
Study: 31806127
Drug: Incremental prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental prophylactic antibiotic treatment
Study: 22315048
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (80 mg caffeine)
Study: 17161119
Drug: Levonorgestrel 90
Normalized name: LEVONORGESTREL 90 ug / ETHINYL ESTRADIOL 20 ug ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 90 μg/ethinyl estradiol 20 μg daily for 1 year
Study: 15753500
Drug: Fast group
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast group (1 mL/sec)
Study: 15753500
Drug: Slow group
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow group (0.05 mL/sec)
Study: 12224975
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (TAC) (20 mg/mL)
Study: 12224975
Drug: Intralesional 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional 5-fluorouracil (5-FU) (50 mg/mL)
Study: 12224975
Drug: Intralesional TAC
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional TAC (1 mg/mL) mixed with 5-FU (45 mg/mL)
Study: 9690971
Drug: Newer antipsychotic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antipsychotic drugs (clozapine, risperidone, olanzapine, amisulpride, quetiapine, sertindole)
Study: 9690971
Drug: Conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotic drugs (haloperidol, chlorpromazine)
Study: 7750167
Drug: Chinese and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese and western medicine treatments
Study: 3383542
Drug: minibag via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: minibag via gravity flow (MG)
Study: 3383542
Drug: minibag with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: minibag with secondary infusion tubing below a volumetric infusion pump (MP)
Study: 3383542
Drug: metered chamber
Normalized name: HOLDING CHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: metered chamber via volumetric infusion pump (MC)
Study: 28830365
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate infusion (25 ml/kg, approximately 2 l over 30 min)
Study: 23325710
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of triamcinolone acetonide (TA)
Study: 21830063
Drug: ivabradine (5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (5-7.5 mg bid) plus bisoprolol 5 mg od
Study: 21830063
Drug: bisoprolol uptitrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol uptitrated to 7.5 mg and then 10 mg od
Study: 17126776
Drug: Transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerine (3-in, 7.5 cm)
Study: 14506196
Drug: (131)I-trace-labeled BsMAb
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I-trace-labeled BsMAb doses escalated from 10 to 100 mg/m(2)
Study: 14506196
Drug: 75 mg/m(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/m(2) BsMAb and 2.6-4.2 GBq of (131)I-hapten
Study: 14506196
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of BsMAb dose to 40 mg/m(2)
Study: 7914795
Drug: Ro 40-2148
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40-2148 (400 mg diluted in 100 ml water, twice a day for 14 days)
Study: 3196390
Drug: Emepronium 25
Normalized name: emepronium 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium 25 mg/kg p.o.
Study: 3196390
Drug: Emepronium 50
Normalized name: emepronium
DrugBank: Emepronium (DB13505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium 50 mg/kg p.o.
Study: 3196390
Drug: Emepronium 100
Normalized name: emepronium 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium 100 mg/kg p.o.
Study: 3196390
Drug: Emepronium 200
Normalized name: emepronium 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium 200 mg q.i.d. in human volunteers
Study: 3196390
Drug: Emepronium 400
Normalized name: emepronium
DrugBank: Emepronium (DB13505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium 400 mg q.i.d. in human volunteers
Study: 25272149
Drug: EPA-enriched n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-enriched n-3 1000 mg/d
Study: 25272149
Drug: DHA-enriched n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched n-3 1000 mg/d
Study: 16934909
Drug: SGN-15 200
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGN-15 200 mg/m2/week with docetaxel 35 mg/m2/week (Arm A)
Study: 16934909
Drug: Docetaxel 35
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 35 mg/m2/week alone (Arm B)
Study: 9266922
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (200 mg of iron sucrose)
Study: 8493761
Drug: Human interferon
Normalized name: Human interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human interferon alpha (HuIFN‐alpha) administered orally
Study: 16724169
Drug: Extended-release oxybutynin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin, 10 mg daily
Study: 16724169
Drug: Extended-release tolterodine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tolterodine, 4 mg daily
Study: 6206316
Drug: Indapamide (IND)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide (IND) 2.5 mg q am
Study: 6206316
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 50 mg q am
Study: 26879816
Drug: Artemisinin conventional
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin conventional formulation (160 mg)
Study: 26879816
Drug: Artemisinin conventional
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin conventional formulation (500 mg)
Study: 26879816
Drug: Artemisinin micronized
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin micronized formulation (160 mg)
Study: 26879816
Drug: Artemisinin micronized
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin micronized formulation (160 mg) with piperaquine phosphate (360 mg)
Study: 26879816
Drug: Increasing dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dose of artemisinin
Study: 14700510
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (amlodipine 5 mg + benazepril 20 mg)
Study: 14700510
Drug: Benazepril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (40 mg)
Study: 10333347
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg
Study: 12473867
Drug: hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide (HCTZ) 25 mg
Study: 9440779
Drug: Immunotherapy using
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy using standardized D. farinae antigen
Study: 2776953
Drug: Intracervical gel
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical gel containing 50 mg 17 beta‐oestradiol
Study: 768851
Drug: L-asparaginase 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase 100 U/kg
Study: 768851
Drug: L-asparaginase 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase 500 U/kg
Study: 768851
Drug: L-asparaginase 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase 1500 U/kg
Study: 768851
Drug: L-asparaginase (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase (all doses)
Study: 30963552
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (ferric carboxymaltose)
Study: 30963552
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulphate)
Study: 25720104
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (continuous negative pressure of -80 mmHg)
Study: 21086117
Drug: Zolpidem (Zp)
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem (Zp) 10 mg
Study: 21086117
Drug: Zopiclone (Zc)
DrugBank: Zopiclone (DB01198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zopiclone (Zc) 7.5 mg
Study: 10889149
Drug: Omeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, amoxicillin, and clarithromycin (OAC) for 1 week; n = 295
Study: 8737958
Drug: trimetazidine 20
Normalized name: trimetazidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimetazidine 20 mg tid
Study: 8737958
Drug: propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 40 mg tid
Study: 1568427
Drug: Steroid electrode
Normalized name: ELECTRODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid electrode (0.5 mg dexamethasone)
Study: 1568427
Drug: Electrode without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrode without steroid
Study: 1568427
Drug: Steroid electrode
Normalized name: ELECTRODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid electrode
Study: 2860153
Drug: Intraperitoneal irrigation
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal irrigation with low molecular weight povidone-iodine solution (PVP-I LMW)
Study: 30539285
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 1g
Study: 30539285
Drug: Topical fibrin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fibrin sealant (FS) 10 ml
Study: 27986480
Drug: vonapanitase 10
Normalized name: Vonapanitase
DrugBank: Vonapanitase (DB11690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonapanitase 10 μg
Study: 27986480
Drug: vonapanitase 30
Normalized name: Vonapanitase
DrugBank: Vonapanitase (DB11690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonapanitase 30 μg
Study: 17695214
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of cyclamate and 22.5 mg of saccharine
Study: 15147226
Drug: Alcohol gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol gel as an adjunct to handwashing
Study: 15147226
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (alcohol gel with handwashing)
Study: 8087484
Drug: Mechanical injection
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical injection
Study: 8087484
Drug: Hand injection
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand injection
Study: 2675668
Drug: Succinylcholine injected
Normalized name: succinylcholine Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine injected at different speeds (20 mg/s, 8 mg/s, 4 mg/s, 2 mg/s, 1 mg/s)
Study: 788751
Drug: Oral indoramin
Normalized name: indoramin
DrugBank: Indoramin (DB08950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral indoramin
Study: 788751
Drug: Intravenous indoramin
Normalized name: indoramin
DrugBank: Indoramin (DB08950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous indoramin